GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (FRA:NVV1) » Definitions » Price-to-Funds-From-Operations

Novavax (FRA:NVV1) Price-to-Funds-From-Operations : (As of Dec. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Novavax Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Novavax Business Description

Industry
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.